Gas Plasma Pre-treatment Increases Antibiotic Sensitivity and Persister Eradication in Methicillin-Resistant Staphylococcus aureus

Li Guo 1*, Ruobing Xu 2, Yiming Zhao 2, Dingxin Liu 1, Zhijie Liu 1, Xiaohua Wang 1, Hailan Chen 3 and Michael G. Kong 1,3,4*

1 State Key Laboratory of Electrical Insulation and Power Equipment, Center for Plasma Biomedicine, Xi’an Jiaotong University, Xi’an, China, 2 School of Life Science and Technology, Xi’an Jiaotong University, Xi’an, China, 3 Frank Reidy Center for Bioelectrics, Old Dominion University, Norfolk, VA, United States, 4 Department of Electrical and Computer Engineering, Old Dominion University, Norfolk, VA, United States

Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of serious nosocomial infections, and recurrent MRSA infections primarily result from the survival of persister cells after antibiotic treatment. Gas plasma, a novel source of ROS (reactive oxygen species) and RNS (reactive nitrogen species) generation, not only inactivates pathogenic microbes but also restores the sensitivity of MRSA to antibiotics. This study further found that sublethal treatment of MRSA with both plasma and plasma-activated saline increased the antibiotic sensitivity and promoted the eradication of persister cells by tetracycline, gentamycin, clindamycin, chloramphenicol, ciprofloxacin, rifampicin, and vancomycin. The short-lived ROS and RNS generated by plasma played a primary role in the process and induced the increase of many species of ROS and RNS in MRSA cells. Thus, our data indicated that the plasma treatment could promote the effects of many different classes of antibiotics and act as an antibiotic sensitizer for the treatment of antibiotic-resistant bacteria involved in infectious diseases.

Keywords: cold atmospheric-pressure plasma, antibiotics resistance, methicillin-resistant Staphylococcus aureus, reactive oxygen species, reactive nitrogen species

INTRODUCTION

Antibiotics are the primary treatment for infectious bacterial diseases (Li et al., 2017). Antibiotic resistance typically emerges several years after the development and use of a new antibiotic, usually within an average of 8 years after introduction (Schmieder and Edwards, 2012). Furthermore, infections with multidrug-resistant bacteria are occurring more frequently, and few or no drugs are available to combat them (Boucher et al., 2009; Wright, 2016; Gonzalez-Bello, 2017). One of the major multidrug-resistant bacteria is methicillin-resistant Staphylococcus aureus (MRSA), which is recognized as a leading cause of nosocomial infections (Shahsavani et al., 2012; Emameini et al., 2017). Persisters are a small non-growing population of bacteria which could also escape from different antibiotics (Levin and Rozen, 2006). Persisters extend the duration of antibiotic treatment, cause the recurrence of infectious diseases, and the generation and ascent of antibiotic resistance (Levin and Rozen, 2006). Increased antibiotic resistance and the shortage of new antibiotics threaten global public health (Boucher et al., 2009; Dwyer et al., 2014). Therefore, strategies to
combat antibiotic resistance, such as the development of new antibiotics or prolonging the lifespan of current antibiotics, are in high demand (Melander and Melander, 2017).

One strategy that has been explored recently is developing approaches that induce bacterial killing via the same mechanism as existing antibiotics. Antibiotics with different targets have been proposed to share a common mechanism of bactericidal activity—enhancing intracellular reactive oxygen species (ROS) in bacterial cells (Kohanski et al., 2007, 2010). Although ROS could be developed as antimicrobials to treat infectious diseases, treatment with these highly reactive molecules is problematic because ROS react non-selectively with such a range of critical, macromolecular targets, which could lead to “off-target” effects (Dharmaraja, 2017). Given that oxidative stress is also associated with antibiotic treatment, low levels of ROS could be used as an adjuvant to potentiate the antibacterial activity of commercial antibiotics (Brynildsen et al., 2013; Morones-Ramirez et al., 2013; Shen et al., 2016). A previous study showed that •OH induced in Ag⁺-treated bacteria potentiated the bactericidal activity of antibiotics against bacterial persisters and biofilms (Morones-Ramirez et al., 2013). Furthermore, fosfomycin, which acts by generating O₂⁻*, was used to successfully treat MRSA infections when combined with many commercial antibiotics (Shen et al., 2016). These strategies relied on the addition of inorganic or organic chemicals, which would bring residues after the treatment.

Cold atmospheric-pressure plasma (referred to as “plasma”) generates many reactive oxygen and nitrogen species (ROS and RNS), such as H₂O₂, •O₂, O₃, •NO, and •OH as well as electrons, ions, and photons. This form of plasma is atmospheric-pressure and near room temperature, thus it treats cells and tissues without thermal damage, making it attractive for a range of biomedical applications, such as bacteria inactivation (Fridman et al., 2008; Moreau et al., 2008; Kong et al., 2009; Kang et al., 2014). The FDA has authorized the use of at least three gas plasma-based products using “plasma biomedicine” technology, such as blood coagulation. In addition, there have been several phase-II clinical trials for plasma-based therapies, such as chronic wound healing, which is the promising applications of plasma in medicine (Isbary et al., 2010, 2012; Heinlin et al., 2013). In the treatment of wounds, the reactive species of plasma could not only kill the microorganisms in the infectious wounds and burns but also increase proliferation of fibroblasts and other cells (Lloyd et al., 2010). Bayliss et al. (2013) found that treating MRSA with sublethal doses of plasma restored the sensitivity of MRSA to trimethoprim, kanamycin, and oxacillin, but the utility of plasma treatment with other types of antibiotics was not studied.

In the present study, in order to further our understanding of the effect of plasma treatment on antibiotic sensitivity, MRSA was treated with both plasma and plasma-activated saline prior to exposure to multiple antibiotics. Sublethal treatment of MRSA with plasma increased the sensitivity of MRSA to seven antibiotics whilst also reducing the numbers of persisters. These results support the use of plasma as an antibiotic sensitizer for the treatment of antibiotic-resistant bacteria involved in infectious diseases.

**MATERIALS AND METHODS**

**Plasma Device and Plasma Treatments**

As shown in **Figure 1A**, the surface discharge structure of the plasma consisted of a high-voltage plane electrode, a liquid-facing grounded mesh electrode of a hexagonal shape and a dielectric layer (made of polytetrafluoroethylene) sandwiched between the two electrodes. The surface plasma was generated when a sinusoidal high voltage was applied and the discharge power density was 0.2 W/cm² with good mesh-to-mesh homogeneity (showed in the front view of the plasmas in **Figure 1A**). One milliliter MRSA suspension or saline in a Petri dish (diameter 35 mm) with the depth of 1 mm was placed under the plasma, whereas the air gap between the plasma and the liquid surface was about 8 mm. The gas plasma system was housed in a sealed organic glass box with a gas flow of helium and 1% artificial air (79% N₂ + 21% O₂) at a constant rate of 4 L/min. The artificial air was used as the source of ROS and RNS, while the helium was used to enhance the production efficiency of those species as well as their fluxes on the treated samples via diffusion.

**Measurement of ROS and RNS Generated by the Plasma**

The concentrations of H₂O₂ and NO₃⁻/NO₂⁻ in 0.9% NaCl were measured using hydrogen peroxide/peroxidase assay kit (Thermo Fisher Scientific) and nitrite/nitrate colorimetric assay kit (Cayman), respectively. •OH, •O₂, •NO, O₂⁻*, •NO₂, and ONOO⁻ were measured using an electron spin-resonance (ESR) spectroscopy (Bruker) together with relevant spin traps. The latter include: 100 mM DMPO (5,5-Dimethyl-1-pyrroline N-oxide, Dojindo), 5 mM MGD (N-(Dithiocarbamoyl)-N-methyl-D-glucamine, Dojindo), 10 mM TEMP (2,2,6,6-Tetramethylpiperidine, TCI), and 10 mM TEMPO-H (1-Hydroxy-2,2,6,6-tetramethyl-4-oxo-piperidine, Enzo).

**Treatment of Staphylococcus aureus With Plasma or Plasma-Activated Saline**

A single S. aureus ATCC33591 colony was grown in 4 ml of Mueller-Hinton (MH) broth (Oxoid) at 225 r.p.m. at 37°C overnight, and the resulting overnight culture was diluted 1:100 in MH and incubated at 37°C for 225 r.p.m. until an OD₆₀₀ of 0.6 was reached. The bacterial cells were collected by centrifugation, washed once with saline (0.9% NaCl) and resuspended in saline at an OD₆₀₀ of 2.0. S. aureus suspensions were treated with plasma directly, or the suspensions were centrifuged and resuspended in plasma-activated saline (saline treated with plasma for the indicated time), saline with 250 µM H₂O₂ + 125 µM NO₂⁻ + 375 µM NO₃⁻, or saline with 500 µM H₂O₂ + 250 µM NO₂⁻ + 750 µM NO₃⁻ and then incubated for 30 min at room temperature. Samples were serially diluted with 0.9% NaCl, and 10 µl of each dilution was spotted onto MH agar plates and incubated overnight at 37°C and the numbers of surviving bacteria were determined by counting the resulting CFUs.

**Determination of Antibiotic Sensitivity**

The S. aureus suspensions prepared as described above were either untreated, treated with plasma directly for 30 or 40 s, or
centrifuged and resuspended in plasma-activated saline (saline treated by plasma for 30 or 40 s), followed by incubation for 30 min at room temperature. Untreated S. aureus, or cells treated with either plasma or plasma-activated saline (100 µl), were plated on MH agar plates. Next, antibiotic susceptibility tests were performed using Etest paper (Biomerieux) for tetracycline (0.016–256 µg/ml), gentamycin (0.016–256 µg/ml), clindamycin (0.016–256 µg/ml), chloramphenicol (0.016–256 µg/ml), ciprofloxacin (0.02–32 µg/ml), rifampicin (0.02–32 µg/ml), and vancomycin (0.016–256 µg/ml) or the Kirby-Bauer method for clindamycin (250, 500, 1,000, and 2,000 µg). Then the plates were cultured overnight at 37°C and bacteriostatic rings were analyzed. The MICs of antibiotics were measured by the microdilution assay using 8–0.016 × MIC of untreated MRSA as described (Lepe et al., 2014).

Quantification of Persister Survival

S. aureus treated with plasma or plasma-activated saline was diluted six times with MH medium containing antibiotics. The final antibiotic concentrations, corresponding to 10× the minimum inhibitory concentration (MIC), were as follows: tetracycline, 500 µg/ml (MP Biomedicals); gentamycin, 200 µg/ml (Sigma); clindamycin, 5,000 µg/ml (TCI); chloramphenicol, 500 µg/ml (MP Biomedicals); ciprofloxacin, 50 µg/ml (Sigma); rifampicin, 4 µg/ml (Sigma); and vancomycin, 50 µg/ml (Sigma). The numbers of surviving bacteria were determined at the time points indicated by harvesting 100 µl of bacterial culture, which was centrifuged at 10,000 × g for 1 min. The resulting pellet was resuspended in 100 µl 0.9% NaCl. Samples were serially diluted, and 10 µl of each dilution was spotted onto MH agar plates and incubated overnight at 37°C and the numbers of surviving bacteria were determined by counting the resulting CFUs.

Detection of Reactive Species in MRSA

The probes 3′-(p-aminophenyl) fluorescein (APF, Sigma), 3′-(p-hydroxyphenyl) fluorescein (HPF, Sigma), and MitoSOX™ Red mitochondrial superoxide indicator (ThermoFisher) were incubated with S. aureus cultures, at a final concentration of 5 µM, and trans-1-(2′-methoxyvinyl)pyrene (tMVP, J&K Scientific) was used at a final concentration of 10 µM at 37°C for 30 min. Cultures were collected by centrifugation, washed with saline (0.9% NaCl) three times and resuspended in saline at an OD600 of 2.0. S. aureus suspensions were untreated, treated with plasma directly for 40 s, or the suspensions were centrifuged and resuspended in plasma-activated saline (saline treated with plasma for 40 s). Immediately after the treatments, the fluorescence intensities were detected using a microplate reader (Thermo Scientific Varioskan Flash) at the excitation and emission wavelengths [APF and HPF: 490/515 nm; superoxide indicator: 510/580 nm; trans-1-(2′-methoxyvinyl)pyrene: 405/460 nm] of each probe.

FIGURE 1 | Measurement of the ROS and RNS diffused into the saline treated with plasma. (A) Diagram of MRSA suspension or saline treated with plasma. (B) The concentrations of ROS, RNS and spin trap adducts diffused into the saline treated with plasma for 30 and 40 s.
RESULTS

Plasma-Induced Aqueous ROS/RNS

MRSA or saline treated with the plasma device was shown in Figure 1A. Gaseous ROS and RNS were generated by the surface discharge, and some of them would diffuse across the air gap and then dissolved into the liquids. The plasma-induced aqueous ROS and RNS dissolved into saline were measured after the plasma treatment for 30s and 40s. Long-lived species H$_2$O$_2$, NO$_2^−$, and NO$_3^−$, as well as the short-lived species •OH, •O$_2^−$, •NO$, and ONOO$^−$, were detected in the saline. The concentrations of aqueous H$_2$O$_2$, NO$_2^−$, and NO$_3^−$ after the plasma treatment for 40s were 23, 14, and 102 µM, respectively (Figure 1B). Electron spin resonance (ESR) spectroscopy was used for the measurement of short-lived species, in which the results were the concentrations of spin adducts, only reflecting the relative concentrations of the specific ROS and/or RNS. The concentrations of spin adducts DMPO-OH, TEMPO, Nitrocyl-Fe, and TEMPONE after the plasma treatment for 40s were 0.1, 69, 21, and 37 µM (Figure 1B). The spin adducts concentrations after the plasma treatment for 30s were lower, such as TEMPO was 30% lower than that after the plasma treatment for 40s. These results suggested that the concentration of aqueous •OH was very low, and the concentration of aqueous •O$_2^−$ should be much larger. The plasma generated many species ROS and RNS, which were thought to play a crucial role in the biological effects.

Sublethal Treatment With Plasma Increased the Sensitivity of MRSA to Antibiotics

The sublethal dose (reduction about 50% viability of MRSA) of plasma and plasma-activated saline were determined by exposing the bacteria to plasma for increasing times or incubating with saline treated with plasma for increasing times and subsequently determining bacterial viability. The treatment of plasma for 40s or the saline activated by plasma for 40s lead to about 50% death of MRSA cells (Figure S1). For safety, a lower dose was also employed, so a slightly lower dose (plasma treatment for 30s) that lead to about 40% death of MRSA cells and the LD$_{50}$ dose (plasma treatment for 40s) were both used to detect the effects on antibiotic sensitivity.

To study the effect of plasma on the sensitivity of MRSA to the antibiotics, MRSA were sublethally pre-treated with plasma or plasma-activated saline followed by incubation with a range of antibiotics including tetracycline, gentamycin, clindamycin, chloramphenicol, ciprofloxacin, rifampicin, and vancomycin. The minimal inhibitory concentration (MIC) of tetracycline for untreated MRSA measured by Etest paper was ∼32 µg/ml, whilst that for MRSA treated with saline activated by plasma for 30s was 10-fold lower, at ∼3 µg/ml (Figure 2B). The MIC of tetracycline against MRSA treated with saline activated for 40s was also 8-fold lower than that against untreated MRSA as indicated by the microdilution assay (Table 1). The MICs of gentamycin, clindamycin, chloramphenicol, ciprofloxacin, rifampicin, and vancomycin against MRSA treated with plasma-activated saline were also lower than those against the untreated MRSA, demonstrating that plasma-activated saline exhibited the same effect in increasing the sensitivity to five different classes of antibiotics (Figures 2B, Figures S2C,D; Table 1).

Plasma Pre-treatment Promoted Eradication of MRSA Persisters

Given that pre-treatment of MRSA with plasma or plasma-activated saline decreased the MIC of multiple antibiotics, we next asked whether either of these pre-treatment conditions could also promote the killing of persisters. To test this, untreated and sublethal dose plasma-treated MRSA were incubated with different antibiotics, as indicated (Figure 3A). Incubation of untreated and double-diluted untreated MRSA with the different antibiotics generally exhibited typical killing curves, with bacterial numbers decreasing from 2 × 10$^8$ to 10$^4$-10$^6$ CFUs, with a small fraction of persisters detected after 3 days of antibiotic exposure. Of note, the numbers of untreated MRSA and double-diluted untreated MRSA that incubated with rifampicin increased after 1 day. These results indicated that the decrease of the initial MRSA numbers did not greatly influence the killing...
FIGURE 2 | Treatment with sublethal doses of plasma or plasma-activated saline increased the sensitivity of MRSA to antibiotics. (A) Direct plasma treatment. (B) Plasma-activated saline treatment. Plasma treated, plasma-activated saline treated and untreated MRSA were plated on MH agar with Etest strips and cultured at 37°C overnight.

TABLE 1 | Antibiotic susceptibilities of Staphylococcus aureus treated with plasma and plasma-activated saline.

| Antibiotics     | Untreated Directly treated with plasma for 30 s | Directly treated with plasma for 40 s | Treated with plasma-activated saline (Saline treated for 30 s) | Treated with plasma-activated saline (Saline treated for 40 s) |
|-----------------|-----------------------------------------------|-------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Tetracycline    | 50                                            | 12.5                                | 6.25                                                          | 12.5                                                          |
| Gentamycin      | 20                                            | 2.5                                 | 1.25                                                          | 1.25                                                          |
| Clindamycin     | 500                                           | 250                                 | 125                                                           | 250                                                           |
| Chloramphenicol | 50                                            | 25                                  | 12.5                                                          | 25                                                            |
| Ciprofloxacin   | 5                                             | 1.25                                | 0.31                                                          | 1.25                                                          |
| Rifampicin      | 0.4                                           | 0.025                               | 0.0125                                                        | 0.025                                                         |
| Vancomycin      | 5                                             | 5                                   | 2.5                                                           | 5                                                             |

MICs were determined by broth microdilution method. The results were read after 24 h of incubation at 37°C.

curves of antibiotics. In contrast, plasma treatment reduced the number of MRSA persisters to below the limit of detection when incubated with tetracycline, gentamycin, clindamycin, chloramphenicol, and rifampicin within only 1 day of exposure (Figure 3A). A similar decrease was also observed within 2 and 3 days of incubation with ciprofloxacin and chloramphenicol, respectively (Figure 3A). For vancomycin, plasma treatment for 30 and 40 s effectively reduced the numbers of remaining MRSA recovered during exposure to this antibiotic to $10^4$ and $10^3$ CFUs, respectively, though these did not drop below the detection limit (Figure 3A). Treatment with plasma-activated saline exhibited the same effect of inactivating persisters as observed by direct plasma treatment (Figure 3B). The numbers of plasma-activated saline treated MRSA recovered upon
exposure to antibiotics tetracycline, gentamycin, clindamycin, and rifampicin dropped to below the detection limit, but plasma-activated saline similarly only decreased the numbers of MRSA to $10^3$ CFUs upon exposure to vancomycin (Figure 3B). These results indicated that both plasma and plasma-activated saline treatment promoted the eradication of MRSA persisters by antibiotics.

**Reactive Species in MRSA**

Plasma-treated solutions contain many active species, such as the long-lived species $H_2O_2$, $NO_2^-$, and $NO_3^-$ as well as the short-lived species $^\cdot OH$, $^1O_2^-$, $^\cdot NO$, $O_2^-$, and $ONOO^-$ (Figure 1B). To evaluate the impact of long-lived species, a mixture of $H_2O_2$ (500 µM), $NO_2^-$ (250 µM), and $NO_3^-$ (750 µM) was used to treat the MRSA. $H_2O_2$, $NO_2^-$, and $NO_3^-$ treatment did not change the antibiotic susceptibility of MRSA and the inactivation of persisters by antibiotics, indicating that the three long-lived species are not likely the direct and driving factor (Figure S3). Hence, short-lived species were considered more important, and the ROS and RNS in MRSA cells were measured. MRSA were incubated with 3′-(p-aminophenyl) fluorescein (APF) for $^\cdot OH$, $ClO^-$, and $ONOO^-$, HPF for $^\cdot OH$ and $ONOO^-$, MitoSOX™ Red mitochondrial superoxide indicator for $O_2^-$ and trans-1-(2′-methoxyvinyl)pyrene (tMVP) for $^1O_2$, then exposed to plasma or plasma-activated saline for 40 s, and the levels of different ROS/RNS determined by changes in the fluorescence intensities (Figure 4). After plasma treatment, the fluorescence intensities of the four probes increased. The fluorescence intensities of MRSA incubated with APF and HPF increased slightly after 30 min of plasma treatment, by 28 and 25%, respectively, which indicates an increase in the levels of $^\cdot OH$, $ClO^-$, and $ONOO^-$ (Figures 4A,B). Fluorescence of MRSA incubated with MitoSOX™ Red mitochondrial superoxide indicator increased by 77%, and the trans-1-(2′-methoxyvinyl)pyrene (tMVP) for $^1O_2$ increased by 130% after 30 min of plasma treatment (Figures 4C,D). The fluorescence intensities of the probes which incubated with plasma-activated saline-treated MRSA were slightly weaker than those of the direct plasma-treated samples. These data suggested that the plasma and plasma-activated saline treatment induced the increases of many species of ROS and RNS in MRSA cells.
**DISCUSSION**

In this study, we demonstrated that treating MRSA sublethally with plasma-generated ROS and RNS decreased the MICs of several antibiotics and increased persister eradication, along with increases in the levels of ROS and RNS in MRSA cells. Plasma-activated saline had the same effect upon the antibiotic sensitivity of MRSA and persister inactivation as direct plasma treatment, suggesting that the plasma-generated ROS and RNS could be applied in both gaseous or aqueous form depending on the mode of application. The short-lived species in the plasma-activated saline had short half-lives, but they could react and generate long-lived species, which also could generate to short-lived species reversibly, such as ONOO\(^-\) generated from NO\(^3\) (Oehmigen et al., 2011; Liu et al., 2017). Plasma generated various ROS, which are involved in a great many chemical reactions (Oehmigen et al., 2011). The underlying reactions and detailed mechanisms of plasma-activated saline are still not well understood and require further study.

Unlike other treatments that have previously been used as antibiotic adjuvants to enhance ROS production in bacterial cells, plasma induces the production of a wider range of ROS species (Morones-Ramirez et al., 2013; Shen et al., 2016). The ROS and RNS generated by the plasma constitute a complex mix of products, including \(\cdot\)OH, \(^1\)O\(_2\), O\(_2^-\), ONOO\(^-\), and ClO\(^-\) (Liu et al., 2016). Subsequently, these many different ROS or RNS species were also detected in plasma-treated bacterial cells. The intracellular ROS and RNS could induce oxidative stresses, such as damaging lipids, proteins and DNA by \(\cdot\)OH, \(^1\)O\(_2\), and O\(_2^-\), as well as protein damages by

**FIGURE 4** | ROS and RNS levels increased in plasma-treated and plasma-activated saline-treated MRSA. MRSA incorporated with APF (A), HPF (B), superoxide indicator (C), and tMVP (D), which measured the ROS or RNS as indicated, treated with plasma for 40 s or saline treated with plasma for 40 s. Then the fluorescence intensities of were measured in plasma-treated, plasma-activated saline-treated, and untreated MRSA. Data are representative of three independent experiments. Error bars represent s.d.
ONOO− and ClO− (Davies, 2016). O2− could be detoxified by endogenous antioxidants of the oxidative response, but no enzyme can detoxify •OH or 1O2, and MRSA could not detoxify all the multiple reactive species induced by plasma (Vatansever et al., 2013). It was speculated that the compound damages stimulated multiple response pathways and kept MRSA busy with repairing, which contributed to the effects of antibiotics.

Reactive species generated by plasma could also induce damages in eukaryotic cells, subsequently, the safety and toxicity of this application should be considered. The CC50 of the plasma treatment used in this study for human primary dermal fibroblasts was about 40 s treatment, which was close to the LD50 on MRSA (Figure S4A). Comparing with bacterial cells, the cultured cells are more easily to be inactivated in vitro because of the lack of cell wall. However, the plasma treatment did not increase micronuclei formation in fibroblast cells (Figures S4B,C). Coincidently, a newly published paper found similar results on lymphocyte TK6 cells (Bekeschus et al., 2018). Further, the olive tail moment of plasma-treated cells exhibited little difference with that of untreated cells (Figures S4D,E). So the plasma treatment did not remarkably increase the mutagenicity of fibroblasts as demonstrated by both micronucleus assay and comet assay. Besides, Maisch et al. (2012) showed that gas plasma could efficiently inactivate S. aureus and Escherichia coli on pig skin without inducing morphological changes or damage-related apoptosis. Clinical trials also demonstrated that 5 min daily treatment with plasma decreased bacteria in chronic wounds of patients without side effects (Isbary et al., 2010). These studies demonstrated the safety of plasma treatment under limited conditions. Many topical biocides are toxic, and the plasma could be developed as alternative, especially the plasma-activated saline could be the safe alternative (Wales and Davies, 2015). When used as a sensitizer with antibiotics as was done in this study, the doses of plasma were much lower than that used for bacteria inactivation, which would reduce the risk of toxicity and improve the safety.

In conclusion, sublethal treatment with plasma-generated ROS and RNS decreased the MICs of several antibiotics and increased persister eradication, along with increases in the levels of ROS and RNS in MRSA. Plasma and plasma-activated saline could be explored as a novel antibiotic sensitizer to generate oxidative stress to combat the increasing problem of antibiotic resistance. Further studies are needed to test these methods against other multidrug-resistant bacteria and to elucidate the underlying mechanism.

AUTHOR CONTRIBUTIONS

LG, RX, and YZ designed and executed most of the experiments and analyzed the data. ZL assisted in the execution of some experiments. LG, DL, and MK wrote the manuscript. MK, LG, DL, XW, and HC reviewed and approved the final version of the manuscript.

ACKNOWLEDGMENTS

This work was supported by National Natural Science Foundation of China (51477136 and 51521065), Doctoral Fund of Ministry of Education of China (2017M613106), Doctoral Fund of Ministry of Education of Shaanxi Province, State Key Laboratory of Agricultural Microbiology (AMLKF201705), State Key Laboratory of Electrical Insulation and Power Equipment (EIPE14123), and Fundamental Research Funds for the Central Universities.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2018.00537/full#supplementary-material

REFERENCES

Bayliss, D. L., Shama, G., and Kong, M. G. (2013). Restoration of antibiotic sensitivity in meticillin-resistant Staphylococcus aureus following treatment with a non-thermal atmospheric gas plasma. Int. J. Antimicrob. Agents 41, 398–399. doi: 10.1016/j.ijantimicag.2012.12.005

Bekeschus, S., Schmidt, A., Kramer, A., Metelmann, H. R., Adler, F., von Woedtke, T., et al. (2018). High throughput image cytometry micronucleus assay to investigate the presence or absence of mutagenic effects of cold physical plasma. Environ. Mol. Mutagen. doi: 10.1002/em.22172. [Epub ahead of print].

Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., et al. (2009). Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin. Infect. Dis. 48, 1–12. doi: 10.1086/595011

Brynilden, M. P., Winkler, J. A., Spina, C. S., MacDonald, I. C., and Collins, J. J. (2013). Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production. Nat. Biotechnol. 31, 160–165. doi: 10.1038/nbt.2458

Davies, M. J. (2016). Protein oxidation and peroxidation. Biochem. J. 473, 805–823. doi: 10.1042/BJ20151227

Dharmaraja, A. T. (2017). Role of Reactive Oxygen Species (ROS) in therapeutics and drug resistance in cancer and bacteria. J. Med. Chem. 60, 3221–3240. doi: 10.1021/acs.jmedchem.6b01243

Doyner, D. J., Belenyk, P. A., Yang, J. H., MacDonald, I. C., Martell, J. D., Takahashi, N., et al. (2014). Antibiotics induce redox-related physiological alterations as part of their lethality. Proc. Natl. Acad. Sci. U.S.A. 111, E2100–E2109. doi: 10.1073/pnas.1401876111

Emaneini, M., Beigverdi, R., van Leeuwen, W. B., Rahdar, H., Karami-Zarandi, M., Hosseinikhani, F., et al. (2017). Prevalence of meticillin-resistant Staphylococcus aureus isolated from burn patients: a systematic review and meta-analysis. J. Glob. Antimicrob. Resist. 12, 202–206. doi: 10.1016/j.jgar.2017.10.015

Fridman, G., Friedman, G., Gutsol, A., Shekhter, A. B., Vasilets, V. N., and Fridman, A. (2008). Applied plasma medicine. Plasma Process. Polym. 5, 503–533. doi: 10.1002/ppap.200700154

Gonzalez-Bello, C. (2017). Antibiotic adjuvants - a strategy to unlock bacterial resistance to antibiotics. Biolog. Med. Chem. Lett. 27, 4221–4228. doi: 10.1016/j.bmccl.2017.08.027

Heinlin, J., Zimmermann, J. L., Zerman, F., Bunk, W., Isbary, G., Landthaler, M., et al. (2013). Randomized placebo-controlled human pilot study of cold atmospheric argon plasma on skin graft donor sites. Wound Repair Regen. 21, 800–807. doi: 10.1111/wrr.12078

Isbary, G., Heinlin, J., Shimizu, T., Zimmermann, J. L., Morfill, G., Schmidt, H. U., et al. (2012). Successful and safe use of 2 min cold atmospheric argon plasma in...
